Physician profile
Anna Piecoro
NPI 1861290637
$666.52
in general payments reported to CMS, 2019-2025
12 companies · $667 in 2025
The $667 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $158.33 | 2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $107.81 | 2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $99.36 | 2025 | Zepbound, Jardiance |
| Genzyme Corporation | $67.12 | 2025 | |
| Abbvie INC. | $54.22 | 2025 | |
| Amgen INC. | $44.61 | 2025 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $40.87 | 2025 | Freestyle Libre 3 |
| Noven Therapeutics, LLC | $23.79 | 2025 | Xelstrym |
| Corium, LLC | $20.92 | 2025 | Azstarys |
| Acella Pharmaceuticals, LLC | $19.22 | 2025 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $15.47 | 2025 | Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $14.80 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Piecoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.